Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Abcellera Biologics Inc (ABCL)

Abcellera Biologics Inc (ABCL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,094,408
  • Shares Outstanding, K 303,160
  • Annual Sales, $ 28,830 K
  • Annual Income, $ -162,860 K
  • EBIT $ -233 M
  • EBITDA $ -136 M
  • 60-Month Beta 0.81
  • Price/Sales 14.57
  • Price/Cash Flow N/A
  • Price/Book 1.13

Options Overview Details

View History
  • Implied Volatility 107.69% (+9.98%)
  • Historical Volatility 92.34%
  • IV Percentile 65%
  • IV Rank 14.58%
  • IV High 352.21% on 04/08/25
  • IV Low 65.96% on 05/09/25
  • Expected Move (DTE 19) 0.72 (20.01%)
  • Put/Call Vol Ratio 1.32
  • Today's Volume 1,079
  • Volume Avg (30-Day) 2,384
  • Put/Call OI Ratio 0.16
  • Today's Open Interest 76,745
  • Open Int (30-Day) 72,558
  • Expected Range 2.89 to 4.33

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.19
  • Number of Estimates 3
  • High Estimate -0.14
  • Low Estimate -0.24
  • Prior Year -0.15
  • Growth Rate Est. (year over year) -26.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.74 +31.51%
on 02/05/26
4.05 -10.86%
on 01/28/26
-0.38 (-9.52%)
since 01/27/26
3-Month
2.74 +31.51%
on 02/05/26
4.85 -25.57%
on 01/22/26
-0.03 (-0.82%)
since 11/26/25
52-Week
1.89 +91.01%
on 04/07/25
6.51 -44.59%
on 10/08/25
+0.69 (+23.63%)
since 02/27/25

Most Recent Stories

More News
AbCellera Reports Full Year 2025 Business Results

AbCellera (Nasdaq: ABCL) today announced financial results for the full year 2025. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. ...

ABCL : 3.61 (+0.56%)
3 New Stocks SoftBank Is Betting Big on in 2026

SoftBank revealed new positions in each of these three companies.

TMUS : 217.09 (+1.85%)
NVDA : 177.19 (-4.16%)
ABCL : 3.61 (+0.56%)
$SPX : 6,878.88 (-0.43%)
CRCL : 83.44 (-4.32%)
XXI : 5.74 (-7.42%)
SFTBY : 13.0600 (-0.91%)
^BTCUSD : 66,896.10 (+2.01%)
AbCellera to Present at Upcoming Investor Conferences in March and April 2026

AbCellera (Nasdaq: ABCL) today announced that the Company will present at the following investor conferences: TD Cowen 46th Annual Health Care Conference, March 4,...

ABCL : 3.61 (+0.56%)
AbCellera to Report Full Year 2025 Financial Results on February 24, 2026

AbCellera (Nasdaq: ABCL) will announce its full year 2025 financial results on Tuesday, February 24, 2026, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time)...

ABCL : 3.61 (+0.56%)
AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

AbCellera (Nasdaq: ABCL) today announced that the first patients have been dosed in the Phase 2 portion of its ongoing Phase 1/2 clinical trial for ABCL635. ABCL635 is a potential first-in-class...

ABCL : 3.61 (+0.56%)
AbCellera and Bruker Reach Global Settlement of Patent Litigation

AbCellera (Nasdaq: ABCL) today announced that it has entered into a settlement and patent license agreement with Bruker Corporation, resolving the patent litigation between the two companies globally....

ABCL : 3.61 (+0.56%)
AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

AbCellera (Nasdaq: ABCL) today announced that the Company will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. A live audio webcast of the presentation...

ABCL : 3.61 (+0.56%)
AbCellera Appoints Dr. Stephen Quake to its Board of Directors

AbCellera (Nasdaq: ABCL) today announced the appointment of Stephen Quake, D.Phil., to its Board of Directors as an independent director. Dr. Quake is a distinguished scientist, inventor,...

ABCL : 3.61 (+0.56%)
AbCellera Reports Q3 2025 Business Results

AbCellera (Nasdaq: ABCL) today announced financial results for the third quarter of 2025. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated....

ABCL : 3.61 (+0.56%)
AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

AbCellera (Nasdaq: ABCL) today announced that the Company will participate in the following investor conferences: Truist Securities BioPharma Symposium, November 6,...

ABCL : 3.61 (+0.56%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635 and ABCL575. AbCellera Biologics Inc. is based in Vancouver, Canada.

See More

Key Turning Points

3rd Resistance Point 3.96
2nd Resistance Point 3.79
1st Resistance Point 3.70
Last Price 3.61
1st Support Level 3.44
2nd Support Level 3.27
3rd Support Level 3.18

See More

52-Week High 6.51
Fibonacci 61.8% 4.75
Fibonacci 50% 4.20
Fibonacci 38.2% 3.66
Last Price 3.61
52-Week Low 1.89

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar